Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 1786 AL 1800

Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond

Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L, Zhang R, Wang H, Chen H.

Transl Neurodegener. 2022 Mar 18;11(1):18. doi: 10.1186/s40035-022-00292-3.

Enhancing autophagy in Alzheimer's disease through drug repositioning

Eshraghi M, Ahmadi M, Afshar S, Lorzadeh S, Adlimoghaddam A, Rezvani Jalal N, West R, Dastghaib S, Igder S, Torshizi SRN, Mahmoodzadeh A, Mokarram P, Madrakian T, Albensi BC, Łos MJ, Ghavami S, Pecic S.

Pharmacol Ther. 2022 Sep;237:108171. doi: 10.1016/j.pharmthera.2022.108171. Epub 2022 Mar 16.

Effects of Supplementation with Probiotics in Experimental Models of Alzheimer's Disease: A Systematic Review of Animal Experiments

Neta FI, de Souza FES, Batista AL, Pinheiro FI, Cobucci RN, Guzen FP.

Curr Alzheimer Res. 2022;19(3):188-201. doi: 10.2174/1567205019666220318092003.

Research progress on lncRNAs in Alzheimer's disease

Xiong WD, Xu KY, Lu L, Li JL.

Yi Chuan. 2022 Mar 20;44(3):189-197. doi: 10.16288/j.yczz.21-427.

Structural Modifications on Chalcone Framework for Developing New Class of Cholinesterase Inhibitors

George G, Koyiparambath VP, Sukumaran S, Nair AS, Pappachan LK, Al-Sehemi AG, Kim H, Mathew B.

Int J Mol Sci. 2022 Mar 14;23(6):3121. doi: 10.3390/ijms23063121.

Sovateltide Mediated Endothelin B Receptors Agonism and Curbing Neurological Disorders

Ranjan AK, Gulati A.

Int J Mol Sci. 2022 Mar 15;23(6):3146. doi: 10.3390/ijms23063146.

Copper-mediated β-amyloid toxicity and its chelation therapy in Alzheimer's disease

Singh SK, Balendra V, Obaid AA, Esposto J, Tikhonova MA, Gautam NK, Poeggeler B.

Metallomics. 2022 Jun 13;14(6):mfac018. doi: 10.1093/mtomcs/mfac018.

Role of Cholinergic Signaling in Alzheimer's Disease

Chen ZR, Huang JB, Yang SL, Hong FF.

Molecules. 2022 Mar 10;27(6):1816. doi: 10.3390/molecules27061816.

Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures

Kim CK, Lee YR, Ong L, Gold M, Kalali A, Sarkar J.

J Alzheimers Dis. 2022;87(1):83-100. doi: 10.3233/JAD-215699.

Pharmacological Exploration of Triazole-based Therapeutics for Alzheimer's Disease: An Overview

Prasanna CAL, Sharma A.

Curr Drug Targets. 2022;23(9):933-953. doi: 10.2174/1389450123666220328153741.

The multimodal action of genistein in Alzheimer's and other age-related diseases

Mas-Bargues C, Borrás C, Viña J.

Free Radic Biol Med. 2022 Apr;183:127-137. doi: 10.1016/j.freeradbiomed.2022.03.021. Epub 2022 Mar 26.

Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: Past, present and future

Gouveia F, Camins A, Ettcheto M, Bicker J, Falcão A, Cruz MT, Fortuna A.

Ageing Res Rev. 2022 May;77:101612. doi: 10.1016/j.arr.2022.101612. Epub 2022 Mar 26.

Molecular Insights into Therapeutic Potentials of Hybrid Compounds Targeting Alzheimer's Disease

Jana A, Bhattacharjee A, Das SS, Srivastava A, Choudhury A, Bhattacharjee R, De S, Perveen A, Iqbal D, Gupta PK, Jha SK, Ojha S, Singh SK, Ruokolainen J, Jha NK, Kesari KK, Ashraf GM.

Mol Neurobiol. 2022 Jun;59(6):3512-3528. doi: 10.1007/s12035-022-02779-6. Epub 2022 Mar 26.

Role of Pharmacogenomics in Individualizing Treatment for Alzheimer's Disease

Argueta N, Notari E, Szigeti K.

CNS Drugs. 2022 Apr;36(4):365-376. doi: 10.1007/s40263-022-00915-3. Epub 2022 Mar 30.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias